Stockscreener 앱 받기
6.31
5.26%
-0.35
전일 마감가:
$6.66
열려 있는:
$6.8
하루 거래량:
392.84K
Relative Volume:
1.71
시가총액:
$115.54M
수익:
$137.27M
순이익/손실:
$-123.57M
주가수익비율:
-0.5728
EPS:
-11.016
순현금흐름:
$-102.89M
1주 성능:
-27.30%
1개월 성능:
-0.32%
6개월 성능:
+50.96%
1년 성능:
-39.76%
1일 변동 폭
$6.25
$6.85
1주일 범위
$6.25
$8.64
52주 변동 폭
$3.51
$10.80
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
명칭
Karyopharm Therapeutics Inc
전화
617-658-0600
주소
85 WELLS AVENUE, NEWTON, MA
KPTI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
6.31 | 121.95M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-13 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | 재개 | H.C. Wainwright | Buy |
| 2023-01-19 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 개시 | Morgan Stanley | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-07-23 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-05 | 재확인 | Robert W. Baird | Outperform |
| 2019-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 재확인 | BofA/Merrill | Underperform |
| 2019-02-27 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 개시 | B. Riley FBR | Buy |
| 2018-11-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-05-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-04-02 | 재개 | Leerink Partners | Outperform |
| 2017-11-15 | 재개 | H.C. Wainwright | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2016-09-08 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-08-18 | 개시 | H.C. Wainwright | Buy |
| 2016-06-28 | 개시 | Robert W. Baird | Outperform |
모두보기
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Aug Spikes: Can Karyopharm Therapeutics Inc disrupt its industryDividend Hike & Verified Entry Point Signals - baoquankhu1.vn
Chart Watch: Will Karyopharm Therapeutics Inc outperform its industry peersJuly 2025 Intraday Action & Technical Pattern Alert System - baoquankhu1.vn
Options Flow: Will Karyopharm Therapeutics Inc 25K0 stock rise with strong economyWeekly Risk Summary & Safe Entry Zone Tips - Bộ Nội Vụ
Layoff Watch: What margin trends mean for Karyopharm Therapeutics Inc stockWeekly Stock Analysis & Accurate Intraday Trading Signals - Bộ Nội Vụ
Analysts Are Bullish on Top Healthcare Stocks: Karyopharm Therapeutics (KPTI), Establishment Labs Holdings (ESTA) - The Globe and Mail
Karyopharm expects phase 3 trial data in myelofibrosis by March - Investing.com Nigeria
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Karyopharm Issues Preliminary 2025 Financial Results and Outlook - TipRanks
Karyopharm (KPTI) Anticipates Transformative 2026 with Key Trial Data - GuruFocus
Karyopharm Therapeutics reports preliminary 2025 revenue of $145 mln - TradingView — Track All Markets
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 - PR Newswire
Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Prospects Need A Boost To Lift Shares - simplywall.st
Is Karyopharm Therapeutics Inc. stock attractive for passive investorsJuly 2025 EndofMonth & Low Drawdown Investment Ideas - Улправда
Why Karyopharm Therapeutics Inc. (25K0) stock could rally stronglyQuarterly Growth Report & Verified Momentum Watchlists - Улправда
Is Karyopharm Therapeutics Inc. stock supported by innovation pipelineEarnings Trend Report & Risk Controlled Swing Alerts - ulpravda.ru
How Karyopharm Therapeutics Inc. stock performs in weak economy2025 Trade Ideas & AI Forecasted Entry and Exit Points - Улправда
Will Karyopharm Therapeutics Inc. (25K0) stock rise with strong economyMarket Growth Summary & Scalable Portfolio Growth Ideas - Улправда
Why Karyopharm Therapeutics Inc. stock attracts global investorsRate Hike & High Accuracy Investment Entry Signals - Улправда
Is Karyopharm Therapeutics Inc. stock attractive for income investorsPortfolio Gains Report & Fast Momentum Entry Tips - Улправда
Will Karyopharm Therapeutics Inc. stock remain a Wall Street favoriteTrend Reversal & Daily Chart Pattern Signals - Улправда
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Cancer therapy company Karyopharm gives new hires 3-year stock grants - Stock Titan
MACD Signal: Why Karyopharm Therapeutics Inc stock attracts global investors2025 Winners & Losers & Safe Capital Growth Tips - Bộ Nội Vụ
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
KPTI (Karyopharm Therapeutics Inc) has impressive results - uspostnews.com
Karyopharm Therapeutics (FRA:25K0) EV-to-OCF : -2.79 (As of Dec. 22, 2025) - GuruFocus
Why Karyopharm Therapeutics Inc. (25K0) stock could be next leader2025 Earnings Impact & Growth Focused Investment Plans - Улправда
Can Karyopharm Therapeutics Inc. stock resist sector downturnsJuly 2025 Market Mood & High Accuracy Trade Alerts - Улправда
Is Karyopharm Therapeutics Inc. stock a bargain at current levelsIndustrial Stocks Review & Free Extraordinary Earning Power - bollywoodhelpline.com
How Karyopharm Therapeutics Inc. stock responds to policy changesWeekly Trend Summary & Fast Entry Momentum Alerts - DonanımHaber
Can Karyopharm Therapeutics Inc. stock withstand economic slowdownJuly 2025 Gainers & Precise Swing Trade Entry Alerts - DonanımHaber
Will Karyopharm Therapeutics Inc. (25K0) stock beat international competitionQuarterly Portfolio Review & Accurate Entry/Exit Alerts - Улправда
Piper Sandler names Karyopharm stock as 2026 top pick, maintains $12 target - Investing.com Canada
Karyopharm Therapeutics’ Earnings Call: Progress Amid Challenges - MSN
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Karyopharm to Participate in Baird's Biotech Discovery Series - Karyopharm
Karyopharm (Nasdaq: KPTI) to discuss myelofibrosis in Baird Biotech Discovery Series chat - Stock Titan
Published on: 2025-12-10 09:05:07 - earlytimes.in
Karyopharm Therapeutics (KPTI) Price Target Decreased by 11.70% to 14.11 - MSN
Is Karyopharm Therapeutics Inc. (25K0) stock among top earnings plays2025 Technical Overview & Safe Capital Growth Tips - Newser
How Karyopharm Therapeutics Inc. (25K0) stock reacts to new regulationsTrade Volume Summary & Daily Stock Trend Watchlist - Newser
What makes Karyopharm Therapeutics Inc. (25K0) stock appealing to growth investorsJuly 2025 Volume & Fast Exit and Entry Strategy Plans - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock outperform global peersJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock split increase liquidity2025 Big Picture & Fast Gaining Stock Reports - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock announce special dividendMarket Growth Summary & Expert Curated Trade Ideas - Newser
Why global investors buy Karyopharm Therapeutics Inc. (25K0) stockJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - Newser
Karyopharm Therapeutics (KPTI) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Karyopharm Therapeutics Inc (KPTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Karyopharm Therapeutics Inc 주식 (KPTI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Paulson Richard A. | President and CEO |
Sep 15 '25 |
Sale |
6.43 |
1,257 |
8,083 |
84,046 |
| Mano Michael | SVP, General Counsel&Secretary |
Sep 15 '25 |
Sale |
6.43 |
234 |
1,505 |
21,425 |
| Poulton Stuart | EVP, Chief Development Officer |
Sep 15 '25 |
Sale |
6.43 |
401 |
2,578 |
27,710 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Sep 15 '25 |
Sale |
6.43 |
408 |
2,623 |
29,390 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
Sep 15 '25 |
Sale |
6.43 |
325 |
2,090 |
35,856 |
| Abate Kristin | Chief Accounting Officer |
Sep 15 '25 |
Sale |
6.43 |
23 |
148 |
10,408 |
| Abate Kristin | Chief Accounting Officer |
Sep 03 '25 |
Sale |
6.78 |
12 |
81 |
9,463 |
| Poulton Stuart | EVP, Chief Development Officer |
Jul 29 '25 |
Sale |
4.37 |
191 |
835 |
27,223 |
| Abate Kristin | Chief Accounting Officer |
Jul 22 '25 |
Sale |
4.00 |
238 |
952 |
9,475 |
| Paulson Richard A. | President and CEO |
May 06 '25 |
Sale |
7.12 |
236 |
1,680 |
82,503 |
4.73%
0.92%
자본화:
|
볼륨(24시간):